Virologic Response at 12 Months of Treatment Predicts Sustained Antiviral Efficacy in Patients with Adefovir-Treated Lamivudine-Resistant Chronic Hepatitis B
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Jung, Young Kul | - |
dc.contributor.author | Yeon, Jong Eun | - |
dc.contributor.author | Han, Woo Sik | - |
dc.contributor.author | Kim, Ji Hoon | - |
dc.contributor.author | Kim, Jeong Han | - |
dc.contributor.author | Park, Jong-Jae | - |
dc.contributor.author | Kim, Jae Seon | - |
dc.contributor.author | Bak, Young-Tae | - |
dc.contributor.author | Yoo, Wangdon | - |
dc.contributor.author | Hong, Sun Pyo | - |
dc.contributor.author | Kim, Soo-Ok | - |
dc.contributor.author | Kwon, So Young | - |
dc.contributor.author | Byun, Kwan Soo | - |
dc.contributor.author | Lee, Chang Hong | - |
dc.date.available | 2020-11-03T05:50:00Z | - |
dc.date.issued | 2010-06 | - |
dc.identifier.issn | 1976-2283 | - |
dc.identifier.issn | 2005-1212 | - |
dc.identifier.uri | https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/14764 | - |
dc.description.abstract | Background/Aims: The aim of our study was to define the potential role of virologic response at 12 months of treatment (VR12) in predicting subsequent virologic and clinical outcomes in adefovir (ADV)-treated lamivudine-resistant chronic hepatitis B. Methods: Two hundred and four patients with lamivudine-resistant chronic hepatitis B virus (HBV) treated with ADV monotherapy were included. Serum HBV DNA was quantified by real-time polymerase chain reactions. VR12 was defined as a HBV DNA level of less than 4 log(10) copies/mL after 12 months of ADV treatment. Results: VR12 was observed in 110 of the 204 patients (54%). The mean HBV DNA reductions from baseline after 12 months of ADV treatment were 3.8 and 1.9 log(10) copies/mL in patients with and without VR12, respectively (p<0.001). The hepatitis B "e" antigen (HBeAg) seroconversion rates in patients with and without VR12 were 32% and 14% at 12 months treatment, respectively (p=0.018), and 40% and 27% at 24 months of treatment (p=0.032). The genotypic mutation rates to ADV in patients with and without VR12 were 0% and 6% at 12 months of treatment, respectively (p=0.033), and 21% and 42% at 24 months (p=0.012). The rates of viral breakthrough in patients with and without VR12 were 0% and 7% at 12 months of treatment, respectively (p=0.072), and 9% and 25% at 24 months (p=0.006). Conclusions: Patients without VR12 may need to switch to or add on other potent antiviral drugs in their medical regimens. (Gut Liver 2010;4:212-218) | - |
dc.format.extent | 7 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | 거트앤리버 발행위원회 | - |
dc.title | Virologic Response at 12 Months of Treatment Predicts Sustained Antiviral Efficacy in Patients with Adefovir-Treated Lamivudine-Resistant Chronic Hepatitis B | - |
dc.type | Article | - |
dc.publisher.location | 대한민국 | - |
dc.identifier.doi | 10.5009/gnl.2010.4.2.212 | - |
dc.identifier.scopusid | 2-s2.0-77953553828 | - |
dc.identifier.wosid | 000278855200009 | - |
dc.identifier.bibliographicCitation | Gut and Liver, v.4, no.2, pp 212 - 218 | - |
dc.citation.title | Gut and Liver | - |
dc.citation.volume | 4 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 212 | - |
dc.citation.endPage | 218 | - |
dc.type.docType | Article | - |
dc.identifier.kciid | ART001569355 | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kciCandi | - |
dc.relation.journalResearchArea | Gastroenterology & Hepatology | - |
dc.relation.journalWebOfScienceCategory | Gastroenterology & Hepatology | - |
dc.subject.keywordPlus | LONG-TERM THERAPY | - |
dc.subject.keywordPlus | E-ANTIGEN | - |
dc.subject.keywordPlus | DIPIVOXIL THERAPY | - |
dc.subject.keywordPlus | HBV INFECTION | - |
dc.subject.keywordPlus | YMDD VARIANTS | - |
dc.subject.keywordPlus | VIRUS LOAD | - |
dc.subject.keywordPlus | EMERGENCE | - |
dc.subject.keywordPlus | DNA | - |
dc.subject.keywordPlus | MUTATIONS | - |
dc.subject.keywordPlus | SELECTION | - |
dc.subject.keywordAuthor | Adefovir dipivoxil | - |
dc.subject.keywordAuthor | Drug resistance | - |
dc.subject.keywordAuthor | Virologic response | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
73, Goryeodae-ro, Seongbuk-gu, Seoul, Republic of Korea (02841)82-2-2286-1265
COPYRIGHT 2020 KOREA UNIVERSITY MEDICAL LIBRARY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.